Does Aetna CVS Cover Zepbound? Plan Types, Prior Authorization, and Appeals

Aetna prescription benefits are run through CVS Caremark, and the answer to whether Aetna and CVS cover Zepbound depends on when you’re asking and what plan you have. CVS Caremark removed Zepbound (tirzepatide) from its standard commercial formularies on July 1, 2025 and replaced it with Wegovy. On May 28, 2026, CVS Caremark announced that Zepbound will return as a preferred option on October 1, 2026. Between those dates, most Aetna commercial members do not have standard formulary coverage for Zepbound, though self-funded employer plans, formulary exceptions, and the sleep apnea indication create real exceptions.1CVS Health. CVS Caremark Delivers Affordability and Access to GLP-1 Weight Management Medications With Expanded Coverage Options

The Current Coverage Timeline

From July 1, 2025 onward, CVS Caremark’s standard control, advanced control, and value formularies stopped covering Zepbound. Wegovy became the preferred GLP-1 drug for weight management on those templates, which affected an estimated 25 to 30 million people.2CNN. Zepbound Wegovy Insurance CVS BCBS Weight Loss Aetna’s Summary of Changes for its Standard Plan listed Zepbound under antiobesity drug removals and pointed members to orlistat, Qsymia, Saxenda, and Wegovy instead.3Aetna. Summary of Changes for Aetna Standard Plan Effective July 1, 2025 CVS Health said the goal was to “use competition to drive lower costs.”

Starting October 1, 2026, Zepbound returns as an additional preferred option alongside Wegovy. CVS Caremark said this followed renewed negotiations with Eli Lilly, and eligible commercially insured patients may pay as little as $25 per month once the change takes effect.4Managed Healthcare Executive. CVS Caremark to Put Zepbound Back on Formulary and Add Foundayo One caveat matters: employers and other plan sponsors can still customize their formularies, so an individual Aetna plan can exclude Zepbound even after CVS Caremark adds it back.

How Coverage Varies by Aetna Plan Type

Aetna’s own clinical policy makes the first point explicit: many Aetna benefit plans contain blanket exclusions for weight-loss drugs, and when a plan carries that exclusion, Zepbound claims will be denied no matter what medical criteria the patient meets.5Aetna. Obesity Surgery Clinical Policy Bulletin Check your specific plan documents before anything else.

Beyond that baseline, coverage splits along these lines:

  • Fully insured employer plans generally follow CVS Caremark’s standard formulary, so Zepbound has been excluded since July 2025 and is scheduled to return in October 2026.
  • Self-funded employer plans can customize independently. Aetna’s employer page confirms employers can choose to include or exclude GLP-1 weight management coverage. Some self-funded plans kept Zepbound on through the 2025 removal.6Aetna. GLP-1 Benefits Coverage
  • ACA Marketplace plans typically track the standard CVS Caremark exclusion.
  • Aetna Medicare Advantage and Part D plans do not cover Zepbound for weight loss. Medicare has historically excluded weight-loss drugs.7Aetna. Does Medicare Cover Ozempic
  • Aetna Better Health (Medicaid) coverage is tightly restricted: adults 18 and older with a BMI of 40 or above who have tried and failed multiple other weight-loss medications.8Aetna. Anti-Obesity Agents Aetna Medicaid Policy

Prior Authorization Even When Covered

Zepbound requires prior authorization on every Aetna plan that covers it. The commercial criteria are the ones most members will deal with.

Standard Commercial Criteria

Under Aetna’s standard non-Medicare commercial policy, a patient seeking Zepbound for weight management must have a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related condition such as high blood pressure, type 2 diabetes, or high cholesterol. The patient must also document six months of participation in a comprehensive weight-management program that includes behavioral modification, a reduced-calorie diet, and increased physical activity, and must continue those lifestyle measures during treatment.9Aetna. Zepbound PA With Limit – Commercial

Initial approval runs eight months. To renew, the patient must have completed at least three months at a stable maintenance dose and must show at least 5% weight loss from baseline, or maintenance of that loss. Continuation approvals last 12 months. Some Aetna commercial plans use a stricter BMI threshold of 35 or higher but keep the same 5% weight-loss renewal rule.10Aetna. Weight Loss BMI 35 GLP-1 Agonists PA With Limit

Medicaid Criteria

The Aetna Better Health bar is higher. The patient must have a BMI of 40 or above, must have tried and failed (or have allergies or contraindications to) all five preferred non-GLP-1 agents (benzphetamine, diethylpropion, orlistat, phendimetrazine, and phentermine), and the prescriber must attest that treatment is intended to avoid bariatric surgery. Initial approval is six months.8Aetna. Anti-Obesity Agents Aetna Medicaid Policy

Sleep Apnea Is Treated Differently

Zepbound received FDA approval in December 2024 for moderate to severe obstructive sleep apnea in adults with obesity.11U.S. Food and Drug Administration. FDA Approves First Medication for Obstructive Sleep Apnea Aetna’s non-Medicare clinical policy covers Zepbound for this indication when the patient has an apnea-hypopnea index of at least 15 events per hour (confirmed by a sleep study) and a BMI of at least 30. Initial approval lasts six months, with 12-month renewals.12Aetna. Zepbound PA With Limit – FE Compatible Aetna Better Health lists sleep apnea as covered while reiterating that weight reduction alone is not.13Aetna Better Health. Zepbound Aetna Medicaid Policy

Access on standard commercial plans during the 2025-2026 removal period has been less clear. Because CVS Caremark pulled Zepbound entirely from its standard formulary, some reporting suggests the exclusion reached the sleep apnea indication too, with self-funded employers as the main exception. The October 2026 reinstatement should resolve the question for plans that adopt the updated formulary.

Requesting a Formulary Exception or Filing an Appeal

If your plan currently excludes Zepbound, a formulary exception is the usual starting point. Your prescriber submits clinical documentation (chart notes, lab results, treatment history) to CVS Caremark’s exceptions team and explains why Zepbound is medically necessary rather than a preferred alternative like Wegovy.14Massachusetts Group Insurance Commission. CVS Caremark Decides to Remove Zepbound From CVS Caremark Formulary A strong case usually includes documented failure of Wegovy, whether from side effects or inadequate response. If the exception is granted, the member pays the Tier 3 copay instead of the full price.

When an exception is denied, Aetna allows a formal appeal within 180 days of the denial notice. You or your representative contact Member Services or submit a written appeal. There may be one or two levels of internal review, with response times from 15 to 60 days. Urgent appeals, where a doctor certifies that waiting would risk your health, are decided within 36 to 72 hours.15Aetna. Claim Denials Your doctor can also request a peer-to-peer review with an Aetna clinician before filing a formal appeal. If internal appeals are exhausted and the denial stands, members on ACA-compliant plans have the right to an external review by an independent third party.16Aetna. Dispute Process

If You Can’t Get Coverage

Eli Lilly runs several savings programs through LillyDirect that can bridge a gap in coverage. All of them expire on December 31, 2026, and none are open to anyone enrolled in Medicare, Medicaid, VA, TRICARE, or any other government-funded healthcare program.17Eli Lilly. Zepbound Savings

  • If you have commercial insurance that covers Zepbound, eligible patients can pay as little as $25 for up to a three-month supply of the single-dose pen, up to $1,300 in annual savings.
  • If you have commercial insurance that doesn’t cover Zepbound, the KwikPen is available at $299 to $449 per month depending on dose.
  • Self-pay patients who agree not to seek reimbursement from any insurer can access the KwikPen at $299 (2.5 mg), $399 (5 mg), and $449 (7.5 mg through 15 mg). The $449 maintenance price requires refills within 45 days of the prior fill.18Eli Lilly. Zepbound Full Terms and Conditions

Without any savings program, wholesale acquisition cost runs from $499 to over $1,086 per fill depending on dose.19Eli Lilly. Zepbound Pricing Info

Medicare beneficiaries have a separate short-term option. The Medicare GLP-1 Bridge is a CMS demonstration running from July 1, 2026 through December 31, 2026, and it operates outside the standard Part D benefit. Eligible beneficiaries in any standalone Part D or Medicare Advantage prescription drug plan can access the KwikPen formulation of Zepbound (or Wegovy) for a $50 monthly copay. Humana is the central claims processor. A provider must submit a prior authorization confirming the patient is 18 or older and meets BMI and comorbidity criteria, such as a BMI of 35 or higher, or a BMI of 30 or higher with conditions like heart failure or chronic kidney disease.20Centers for Medicare & Medicaid Services. Medicare GLP-1 Bridge